Literature DB >> 709212

Disentangling Kaposi's sarcoma.

.   

Abstract

Entities:  

Mesh:

Year:  1978        PMID: 709212      PMCID: PMC1608193     

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  9 in total

1.  Leukemia or lymphoma and coexistent primary malignant lesions: a review of the literature and a study of 120 cases.

Authors:  C G MOERTEL; A B HAGEDORN
Journal:  Blood       Date:  1957-09       Impact factor: 22.113

2.  Kaposi's sarcoma after long-term alkylating agent therapy for multiple myeloma.

Authors:  S B Kapadia; J R Krause
Journal:  South Med J       Date:  1977-08       Impact factor: 0.954

3.  Malignant tumors arising de novo in immunosuppressed organ transplant recipients.

Authors:  I Penn; T E Starzl
Journal:  Transplantation       Date:  1972-10       Impact factor: 4.939

4.  Risk of cancer in renal-transplant recipients.

Authors:  R Hoover; J F Fraumeni
Journal:  Lancet       Date:  1973-07-14       Impact factor: 79.321

5.  Radiotherapy of Kaposi's sarcoma.

Authors:  M J Holecek; A R Harwood
Journal:  Cancer       Date:  1978-05       Impact factor: 6.860

6.  Treatment of Kaposi's sarcoma with a combination of actinomycin D and vincristine. Results of a randomized clinical trial.

Authors:  C L Vogel; A Primack; D Dhru; P Briers; R Owor; S K Kyalwazi
Journal:  Cancer       Date:  1973-06       Impact factor: 6.860

7.  Herpes-type virus particles in tissue culture of Kaposi's sarcoma from different geographic regions.

Authors:  G Giraldo; E Beth; F Haguenau
Journal:  J Natl Cancer Inst       Date:  1972-12       Impact factor: 13.506

8.  Growth kinetics of Kaposi's sacroma.

Authors:  J F Taylor; O H Iversen; R Bjerknes
Journal:  Br J Cancer       Date:  1977-04       Impact factor: 7.640

9.  Delayed cutaneous hypersensitivity reactions in patients with Kaposi's sarcoma.

Authors:  J F Taylor; J L Ziegler
Journal:  Br J Cancer       Date:  1974-10       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.